Biogenvs.Vertex Pharmaceuticals
BIIB vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 4.1× larger than Biogen by market cap; Biogen trades at the lower P/E (21.3 vs 27.9); year to date, Biogen leads (+13.2% vs +7.1%).
Side by side
| BIIB | VRTX | |
|---|---|---|
| Market cap | $29.3B | $121B |
| Price | $199.15 | $485.39 |
| Today | +0.1% | −2.2% |
| Return YTD | +13.2% | +7.1% |
| Return 1Y | +47.2% | +1.2% |
| P/E | 21.3 | 27.9 |
| P/S | 2.9 | 9.9 |
| P/B | 1.6 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where BIIB and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →